[go: up one dir, main page]

PE20230486A1 - Polipeptidos y sus usos - Google Patents

Polipeptidos y sus usos

Info

Publication number
PE20230486A1
PE20230486A1 PE2022001740A PE2022001740A PE20230486A1 PE 20230486 A1 PE20230486 A1 PE 20230486A1 PE 2022001740 A PE2022001740 A PE 2022001740A PE 2022001740 A PE2022001740 A PE 2022001740A PE 20230486 A1 PE20230486 A1 PE 20230486A1
Authority
PE
Peru
Prior art keywords
seq
amino acid
acid sequence
polypeptide
present
Prior art date
Application number
PE2022001740A
Other languages
English (en)
Inventor
Neil P King
Carl Walkey
Jing Yang Wang
Brooke Fiala
David Veesler
Alexandra C Walls
Una Nattermann
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of PE20230486A1 publication Critical patent/PE20230486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Referido a un polipeptido que comprende o consiste en: (a) una secuencia de aminoacidos al menos 75 %, 80 %, o hasta 99 % identica a la secuencia de aminoacidos de la SEQ ID NO:1 (I3-01 de tipo silvestre), en donde 1, 2, 3, 4, 5, 6, 7, 8, 9 o las 10 mutaciones siguientes con relacion a la SEQ ID NO:1 estan presentes en el polipeptido: F32Y, H37D/E/K/N/Q/R, F43Q, entre otros; (b) una secuencia de aminoacidos al menos 75 %, 80 %, o hasta 99 % identica a la secuencia de aminoacidos de la SEQ ID NO: 2 (tetramero O43-38 de tipo silvestre), en donde 1, 2, 3, 4, 5, 6, 7, 8 o las 9 de las siguientes mutaciones con relacion a la SEQ ID NO:2 estan presentes en el polipeptido: M138D/E/K/N/Q/R/S/T, L139D/N/S, A141S, entre otros; (c) una secuencia de aminoacidos al menos 75 %, 80 %, o hasta 99 % identica a la secuencia de aminoacidos de la SEQ ID NO:3 (trimero O43-38 de tipo silvestre), en donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 o las 21 de las siguientes mutaciones con relacion a la SEQ ID NO:3 estan presentes en el polipeptido: R17D/E/K/N/Q/S/T, N19D/E, S20D/E/K/N, entre otros; (d) una secuencia de aminoacidos al menos 75 %, 80 %, o hasta 99 % identica a la secuencia de aminoacidos de la SEQ ID NO:4 (I53_dn5A de tipo silvestre), en donde 1, 2, 3, 4, 5, 6, 7, 8, 9 o las 10 de las siguientes mutaciones con relacion a la SEQ ID NO:4 estan presentes en el polipeptido: R17T, W18D/E/K/N/Q/R/S/T/Y, N19E, E21D, entre otros; o (e) una secuencia de aminoacidos al menos 75 %, 80 %, o hasta 99 % identica a la secuencia de aminoacidos de la SEQ ID NO:5 o 6 (hMPV de tipo silvestre), en donde 1, 2, 3, 4 o las 5 de las siguientes mutaciones con relacion a la SEQ ID NO:5 o 6 estan presentes en el polipeptido: A107D, V112R, T114E, V118R y/o G264D; en donde los residuos entre parentesis son opcionales y pueden estar presentes o pueden estar ausentes en su totalidad o en parte. Tambien se refiere a una proteina de fusion que comprende dicho polipeptido, nanoparticulas y una composicion que comprende dichos polipeptidos, metodos para disenarlos, acido nucleico que codifica dicho polipeptido, vector de expresion, celula hospedera, y metodos para disenar tales polipeptidos.
PE2022001740A 2020-02-14 2021-02-12 Polipeptidos y sus usos PE20230486A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
PCT/US2021/017856 WO2021163481A1 (en) 2020-02-14 2021-02-12 Polypeptides and their use

Publications (1)

Publication Number Publication Date
PE20230486A1 true PE20230486A1 (es) 2023-03-21

Family

ID=77292738

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001740A PE20230486A1 (es) 2020-02-14 2021-02-12 Polipeptidos y sus usos

Country Status (10)

Country Link
US (1) US20230075095A1 (es)
EP (1) EP4103586A4 (es)
JP (1) JP2023513592A (es)
KR (1) KR20220142471A (es)
AU (1) AU2021220958A1 (es)
BR (1) BR112022016197A2 (es)
CL (1) CL2022002215A1 (es)
CO (1) CO2022011395A2 (es)
PE (1) PE20230486A1 (es)
WO (1) WO2021163481A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114933657B (zh) * 2021-08-25 2024-02-02 上海交通大学医学院 神经生长因子突变体重组蛋白及其应用
KR102527221B1 (ko) * 2021-10-15 2023-05-02 에스케이바이오사이언스 주식회사 단백질의 정제방법
US20250215055A1 (en) * 2022-04-07 2025-07-03 University Of Washington Secretion-optimized de novo designed protein nanoparticles for eukaryotic expression and genetic delivery
TW202446784A (zh) 2023-05-01 2024-12-01 華盛頓大學 融合前穩定的ｃｍｖ ｇｂ蛋白奈米結構
TW202515998A (zh) * 2023-09-15 2025-04-16 美商伊科薩瓦克斯有限公司 病毒蛋白質及奈米結構及其用途
WO2025144636A1 (en) * 2023-12-26 2025-07-03 The Scripps Research Institute ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2025207938A1 (en) * 2024-03-29 2025-10-02 University Of Washington Nucleic acid vaccines against coccidioidomycosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1756145T3 (da) * 2004-06-16 2014-09-29 Dsm Ip Assets Bv Produktion af polypeptider ved hjælp af forbedret sekretion
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
US10501733B2 (en) * 2015-02-27 2019-12-10 University Of Washington Polypeptide assemblies and methods for the production thereof
EP3683308A1 (en) * 2015-06-10 2020-07-22 Toyama Prefectural University Active-form mutant enzyme production method, new active-form mutant enzyme, and solubilized mutant protein production method
JP6957039B2 (ja) * 2016-09-06 2021-11-02 学校法人慶應義塾 融合タンパク質、構造体、捕集剤、捕集する方法、ｄｎａ、及びベクター
WO2018148647A2 (en) * 2017-02-10 2018-08-16 Lajoie Marc Joseph Genome editing reagents and their use
AU2018249533C1 (en) * 2017-04-04 2023-10-12 Institute For Research In Biomedicine Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
EP3758747A1 (en) * 2018-02-28 2021-01-06 University of Washington Self-asssembling nanostructure vaccines
FR3083804B1 (fr) * 2018-07-13 2022-08-12 Institut Nat Des Sciences Appliquees De Toulouse Micro-organismes et procede pour la production d'acide glycolique a partir de pentoses et d'hexoses

Also Published As

Publication number Publication date
CL2022002215A1 (es) 2023-05-05
CO2022011395A2 (es) 2023-01-16
EP4103586A4 (en) 2024-05-15
KR20220142471A (ko) 2022-10-21
WO2021163481A1 (en) 2021-08-19
EP4103586A1 (en) 2022-12-21
AU2021220958A1 (en) 2022-09-01
BR112022016197A2 (pt) 2022-10-25
JP2023513592A (ja) 2023-03-31
US20230075095A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
PE20230486A1 (es) Polipeptidos y sus usos
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
Hodel et al. In chromaffin cells, the mammalian Sec1p homologue is a syntaxin 1A-binding protein associated with chromaffin granules.
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
Finn et al. Evolution and functional diversity of aquaporins
AR110502A1 (es) Polinucleótidos y polipéptidos de adenovirus
MX2024015050A (es) L-asparaginasa modificada
AR123978A1 (es) Variantes de la interleucina-18 y métodos de uso
DE69434083D1 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
DK1844150T3 (da) Rekombinant ekspression af proteiner i en to-kædet form med disulfidbroer
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
WO2021198706A3 (en) Coronavirus vaccines
DE69839553D1 (de) Verfahren zur herstellung von proteinen
AR065074A1 (es) Peptidos de senalizacion
PE20220706A1 (es) Muteinas de interleucina-2 para la expansion de celulas t reguladoras
AR123158A1 (es) Proteínas de fusión del ligando para flt3 y métodos de uso
AR122047A2 (es) Polipéptido recombinante aislado con actividad pesticida, composición pesticida, molécula de ácido nucleico, célula huésped, construcción de adn, vector, método para producir dicho polipéptido y método para producir una planta transgénica
CO2023003453A2 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
CO2023000048A2 (es) Conjugados de citoquina
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
PE20200385A1 (es) Variantes de proteina morfogenica osea humana 7 (bmp7)
EA202092065A1 (ru) ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA)
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
PE20010238A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS SodC, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS